CN105084393A - Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same - Google Patents
Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same Download PDFInfo
- Publication number
- CN105084393A CN105084393A CN201410184771.0A CN201410184771A CN105084393A CN 105084393 A CN105084393 A CN 105084393A CN 201410184771 A CN201410184771 A CN 201410184771A CN 105084393 A CN105084393 A CN 105084393A
- Authority
- CN
- China
- Prior art keywords
- weight
- consumption
- formula
- corrosion
- polyvinylpyrrolidone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Manganese hexacyanoferrate crystalline nanoparticles and a preparation method for nuclear magnetic resonance contrast agent using the same. The invention relates to compound crystalline nanoparticles represented by the molecular formula Mn3[Fe(CN)6]2(H2O)n, wherein n=0-13, and a preparation method for nuclear magnetic resonance contrast agent using the same. The compound crystalline nanoparticles can be used for nuclear magnetic resonance contrast agent.
Description
Technical field
The present invention relates to a kind of molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
nthe preparation method of compound crystal nanometer and mri contrast agent thereof, wherein n=0-13, this compound crystal nanoparticle can be used as mri contrast agent.
Background technology
The present invention relates to a kind of molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
nthe preparation method of compound crystal nanometer and mri contrast agent thereof, wherein n=0-13, this compound crystal nanoparticle can be used as mri contrast agent.
Summary of the invention
The invention provides a kind of molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
nthe preparation method of compound crystal nanometer and mri contrast agent thereof, this compound crystal nanoparticle can be used as mri contrast agent.
1, molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein preparation of the compound crystal of n=0-13, mainly comprises the following steps:
With six cyanogen iron complexing ion [Fe (CN)
6]
3-with divalent manganesetion Mn
2+by hybrid reaction, obtain crystallization, by this Crystallization Separation out after at 50 DEG C of freeze-day with constant temperature to constant weight, obtaining molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein compound crystal of n=0-13.
Wherein six cyanogen iron complexing ion [Fe (CN)
6]
3-, by [Fe (CN) 6]
3-concentration is 0.01-0.50 mole
-calculate, by dissolve in the following aqueous solution containing [Fe (CN) 6]
3-compound dissolution in the aqueous citric acid solution of 0.1%-20% (weight), be called A1, or be dissolved in 0.1%-20% (weight) aqueous tartaric acid solution and be called A2, or be dissolved in lactic acid: be called A3 in the lactic acid aqueous solution of the volume ratio 1: 1-20 of water;
Wherein divalent manganesetion Mn
2+, by Mn
2+concentration is 0.01-0.50 mole of calculating, by solubility containing Mn
2+compound dissolution in the aqueous citric acid solution of 0.1%-20% (weight), be called B1, or be dissolved in 0.1%-20% (weight) aqueous tartaric acid solution and be called B2, or be dissolved in lactic acid: be called B3 in the lactic acid aqueous solution of the volume ratio 1: 1-20 of water;
A1 to be poured in B1 to obtain into C1, or A1 to be poured in B2 to obtain into C2, or A1 to be poured in B3 to obtain into C3;
A2 to be poured in B1 to obtain into D1, or A2 to be poured in B2 to obtain into D2, or A2 to be poured in B3 to obtain into D3;
A3 to be poured in B1 to obtain into E1, or A3 to be poured in B2 to obtain into E1, or A3 to be poured in B3 to obtain into E3.
Above-mentioned hybrid mode obtains CI, C2, C3, D1, D2, D3, E1, E2, E3 crystallization, and after separating, within the scope of 45 DEG C-65 DEG C, freeze-day with constant temperature is to constant weight, and obtaining its molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein crystallization of n=0-13, crystalline particle particle diameter is between 0.2-120 micron, and the x-ray diffractogram of powder of crystallization is shown in Fig. 1.
2, molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, wherein the preparation of the nanoparticle of the compound crystal of n=0-13 mainly comprises the following steps:
Be Mn by molecular formula
3[Fe (CN)
6]
2(H
2o)
n, wherein the compound crystal corrosion of n=0-13 is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, Zonon D, halfcystine at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, Zonon D at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, halfcystine at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, Zonon D, halfcystine at formula, or corrosion is in N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, cigarette aqueous acid at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, Zonon D at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, halfcystine at formula, it is transparent that above-mentioned corrosion process need constantly be stirred to solution, in above-mentioned corrosion process, polyvinylpyrrolidone can use chitosan, or available dextran, or available carboxyl dextran, or available dextran, or available Sensor Chip CM 5, or available polyoxyethylene glycol substitutes, in above-mentioned each formula, the consumption of composition is respectively: N.F,USP MANNITOL consumption is 3-20% (weight), meglumine consumption is 1.0%-25% (weight), polyvinylpyrrolidone consumption is 1.5%-20% (weight), chitosan dosage is 1.5%-15% (weight), dextran consumption is 1.5%-15% (weight), carboxyl dextran consumption is 1.5%-15% (weight), dextran consumption is 1.5%-15% (weight), Sensor Chip CM 5 consumption is 1.5%-15% (weight), polyoxyethylene glycol consumption is 1.5%-15% (weight), nicotinic acid consumption is 0.01-5.0% (weight), Zonon D consumption is 0.01-5.0% (weight), bladder propylhomoserin consumption is 0.01%-5.0% (weight), in said process, continue after each composition adds to stir 0.5-36 hour, the molecular formula forming stable transparent is Mn
3[Fe (CN)
6]
2(H
2o)
nthe nano-particle solution of compound crystal.Divalent manganesetion content is between 0.1-400mM, and PH is between 7.60-12.50, and Nanoparticle Size is between 0.1nm-200nm.
3, molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, wherein the preparation of the compound crystal nano-NMR contrast medium of n=0-13 mainly comprises the following steps:
Be Mn by prepared molecular formula
3[Fe (CN)
6]
2(H
2o)
nwherein the nano-particle solution of the compound crystal of n=0-13 is mixed with the concentration containing manganese 2-50mM, through 0.22 μm of millipore filtration sterile filtration, aseptic subpackaged in cillin bottle, i.e. obtained liquid Manganese hexacyanoferrate crystallization nano-NMR contrast medium, can use by injection for intravenous;
Be Mn by prepared molecular formula
3[Fe (CN)
6]
2(H
2o)
nwherein the nano-particle solution of the compound crystal of n=0-13 is mixed with the concentration containing manganese 2-50mM, through 0.22 μm of millipore filtration sterile filtration, gained filtrate, through aseptic spray chilling vacuum-drying or vacuum lyophilization process, obtains dry powder, aseptic subpackaged in cillin bottle, i.e. obtained solid-state Manganese hexacyanoferrate crystallization nano-NMR contrast medium, use front water for injection or injection normal saline dilution, be made into the concentration containing manganese 2-50mM, can use by injection for intravenous.
4, molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, wherein the nanoparticle mri contrast agent of the compound crystal of n=0-13 shows for big white mouse magnetic resonance imaging result:
The remarkable blast of T1 contrastographic picture, signal enhancement value is more than 2 times of blank signal, sees Fig. 4, Fig. 5;
Big white mouse after radiography experiment is raised 2 weeks, period its outward appearance and behavior no abnormality seen.
Accompanying drawing explanation
Fig. 1 is the molecular formula prepared by the embodiment of the present invention 1 is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein compound crystal of n=0-13, its powder x-ray diffraction figure is Fig. 1.
Fig. 2 is the molecular formula prepared by the embodiment of the present invention 2 is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein nano-particle solution of the compound crystal of n=0-13, the nano-particle solution transmission electron microscope observing of its crystallization to nanoparticle be Fig. 2, nano particle diameter is between 1-10nm.
Fig. 3 is the molecular formula prepared by the embodiment of the present invention 2 is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein nano-particle solution of the compound crystal of n=0-13, doing ultimate analysis energy spectrogram through transmission electron microscope is Fig. 3, does not measure the absorption peak of potassium, and the ratio recording manganese and iron is approximately 1.5: 1.
Fig. 4 is the molecular formula prepared by the embodiment of the present invention is Mn
3[Fe (CN)
6]
2(H
2o)
nthe wherein nano-particle solution of the compound crystal of n=0-13, through being prepared into the intravenous injection sample containing manganese 7mM, by the dosage of 1ml/300g by before in tail vein injection to big white mouse body, do magnetic resonance imaging, obtain magnetic resonance imaging T1 image and the signal value of the rat liver before injection.
Fig. 5 is the molecular formula prepared by the embodiment of the present invention is Mn
3[Fe (CN)
6]
2(H
2o)
nthe wherein nano-particle solution of the compound crystal of n=0-13, through being prepared into the intravenous injection sample containing manganese 7mM, by the dosage of 1ml/300g by tail vein injection in big white mouse body, do magnetic resonance imaging, the magnetic resonance imaging T1 image of rat liver and signal value when must inject latter 20 minutes.
Embodiment
Embodiment 1:
Mn
3[Fe (CN)
6]
2(H
2o)
n, the preparation of the wherein Manganese hexacyanoferrate crystallization of n=0-13
Take 843 milligrams of K
3[Fe (CN)
6] put into 100 ml beakers, add the complete corrosion of 10% aqueous citric acid solution 25ml, be called for short sample A; Take 495 milligrams of MnCl
24H
2o puts into 100 ml beakers, adds lactic acid: the lactic acid aqueous solution 25ml of the volume ratio 1: 10 of water dissolves completely, is called for short sample B; A sample is poured in the beaker of B sample, beaker mouth is sealed with sealing compound, under lucifuge, room temperature leaves standstill 12 hours, there is a large amount of fine crystalline to produce, with 0.22-0.45 μm of filtering with microporous membrane, crystallize to that filtrate PH is unchanged by washed with de-ionized water, by the crystallization after cleaning, at 50 DEG C, freeze-day with constant temperature is to constant weight, and obtaining molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein Manganese hexacyanoferrate crystallization of n=0-13, its x-ray diffractogram of powder is shown in Fig. 1.
Embodiment 2:
Molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the preparation of the nanoparticle of the wherein Manganese hexacyanoferrate crystallization of n=0-13
Take 8.50g N.F,USP MANNITOL, add water to 65ml, add meglumine 16.00g, nicotinic acid 0.0218g, Zonon D 0.0484g, halfcystine 0.0361g, polyvinylpyrrolidone 9.00g again, continuous stirring, and be progressively heated to 60 DEG C, maintain 60 DEG C and dissolve completely to polyvinylpyrrolidone, solution is that micro-Huang is transparent, and then be cooled to room temperature, be called for short sample A.
Taking molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, wherein the Manganese hexacyanoferrate crystallization 0.224g of n=0-13 joins in sample A, constantly stirs, and to the complete corrosion of this crystallization, solution is amber transparent, and continue stirring 12 hours, obtaining molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
n, the wherein Manganese hexacyanoferrate crystalline nanoparticles solution of n=0-13, is called for short sample B.The pH value recording sample B is 10.0; Nanoparticle equiblibrium mass distribution in the solution in transmission electron microscope observation to sample B, particle diameter, at 1-10nm, is shown in Fig. 2; The ratio that transmission electron microscope ultimate analysis power spectrum records sample B manganese and iron is 1.5: 1, has no potassium peak, sees Fig. 3;
Embodiment 3:
Be Mn by molecular formula prepared in embodiment 2
3[Fe (CN)
6]
2(H
2o)
n, wherein the nano-particle solution sample B of the compound crystal of n=0-13 is mixed with the concentration containing manganese 7mM, through 0.22 μm of millipore filtration sterile filtration, aseptic subpackaged in cillin bottle, namely obtained liquid Manganese hexacyanoferrate crystallization nano-NMR contrast medium, is called for short sample C, can use by injection for intravenous;
Embodiment 4:
Be Mn by molecular formula prepared in embodiment 2
3[Fe (CN)
6]
2(H
2o)
nwherein the nano-particle solution sample B of the compound crystal of n=0-13 is mixed with the concentration containing manganese 7mM, and through 0.22 μm of millipore filtration sterile filtration, gained filtrate is through sterile cryo vacuum drying treatment, obtain dry powder, aseptic subpackaged in cillin bottle, namely obtained solid-state Manganese hexacyanoferrate crystallization nano-NMR contrast medium, is called for short sample D, use front water for injection or injection normal saline dilution, be made into the concentration containing manganese 7mM, be called for short sample E, can use by injection for intravenous.
Embodiment 5:
By the sample C that obtains in embodiment 4 by the dosage of 1ml/300g by tail vein injection in big white mouse body, do magnetic resonance imaging experiment, the rat liver magnetic resonance imaging T1 image before sample C must be injected, see Fig. 4; When must inject after sample C 20 minutes, the magnetic resonance imaging T1 image of rat liver and signal value, be shown in Fig. 5.The remarkable blast of rat liver image after injection sample C, signal value is more than 2 times before injection sample C.Big white mouse after injection C sample is raised 2 weeks, period big white mouse outward appearance and behavior no abnormal.
Claims (12)
1. a molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
nthe preparation method of compound crystal nanometer and contrast medium thereof, wherein n=0-13.
2. molecular formula is Mn according to claim 1
3[Fe (CN)
6]
2(H
2o)
nthe preparation method of compound crystal nanometer is that first to prepare molecular formula be Mn
3[Fe (CN)
6]
2(H
2o)
ncompound crystal, wherein n=0-13, then be Mn by this crystalline molecular formula
3[Fe (CN)
6]
2(H
2o)
ncompound crystal nanometer.
3. compound crystal according to claim 2, is characterized in that, with six cyanogen iron complexing ion [Fe (CN)
6]
3-with divalent manganesetion Mn
2+, by hybrid reaction, obtaining molecular formula is Mn
3[Fe (CN)
6]
2(H
2o)
nthe crystallization of compound, wherein n=0-13.
4. six cyanogen iron complexing ions [Fe (CN) 6] according to claim 3
3-, it is characterized in that, by [Fe (CN) 6]
3-concentration is 0.01-0.50 mole of calculating, by dissolve in the following aqueous solution containing [Fe (CN) 6]
3-compound dissolution 0.1%-20% (weight) aqueous citric acid solution or be dissolved in 0.1%-20% (weight) aqueous tartaric acid solution or be dissolved in lactic acid: in the lactic acid aqueous solution of the volume ratio 1: 1-20 of water.
5. divalent manganesetion Mn according to claim 3
2+, it is characterized in that, by Mn
2+concentration is 0.01-0.50 mole of calculating, by dissolve in the following aqueous solution containing Mn
2+compound corrosion 0.1%-20% (weight) aqueous citric acid solution or be dissolved in 0.1%-20% (weight) aqueous tartaric acid solution or be dissolved in lactic acid: in the lactic acid aqueous solution of the volume ratio 1: 1-20 of water.
6. molecular formula is Mn according to claim 3
3[Fe (CN)
6]
2(H
2o)
nthe crystallization of compound, the crystalline powder X-ray diffractogram of this compound is Fig. 1.
7. molecular formula is Mn according to claim 3
3[Fe (CN)
6]
2(H
2o)
nthe crystallization of compound, crystalline particle particle diameter is between 0.2-120 micron.
8., according to claim 3, be Mn by molecular formula
3[Fe (CN)
6]
2(H
2o)
nthe crystallization corrosion of compound is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, Zonon D, halfcystine at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, Zonon D at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, nicotinic acid, halfcystine at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, Zonon D, halfcystine at formula, or corrosion is in N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, cigarette aqueous acid at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, Zonon D at formula, or corrosion is in the aqueous solution of N.F,USP MANNITOL, meglumine, polyvinylpyrrolidone, halfcystine at formula, it is transparent that above-mentioned corrosion process need constantly be stirred to solution, in above-mentioned corrosion process, polyvinylpyrrolidone can use chitosan, or available dextran, or available carboxyl dextran, or available dextran, or available Sensor Chip CM 5, or available polyoxyethylene glycol substitutes, in above-mentioned each formula, the consumption of composition is respectively: N.F,USP MANNITOL consumption is 2-20% (weight), meglumine consumption is 1.0%-25% (weight), polyvinylpyrrolidone consumption is 1.5%-20% (weight), chitosan dosage is 1.5%-15% (weight), dextran consumption is 1.5%-15% (weight), carboxyl dextran consumption is 1.5%-15% (weight), dextran consumption is 1.5%-15% (weight), Sensor Chip CM 5 consumption is 1.5%-15% (weight), polyoxyethylene glycol consumption is 1.5%-15% (weight), nicotinic acid consumption is 0.01-5.0% (weight), Zonon D consumption is 0.01-5.0% (weight), halfcystine consumption is 0.01%-5.0% (weight), in said process, continue after each composition adds to stir 0.5-36 hour, the molecular formula forming stable transparent is Mn
3[Fe (CN)
6]
2(H
2o)
nthe nano-particle solution of compound crystal.
9. nano-particle solution according to claim 8, divalent manganesetion content is between 0.1-400mM.
10. nano-particle solution according to claim 8, is characterized in that PH is between 7.60-12.50.
11. nano-particle solution according to claim 8, is characterized in that described Nanoparticle Size is between 0.1nm-200nm.
12. nano-particle solution according to claim 8, is characterized in that described nano-particle solution or its lyophilized powder can be used as mri contrast agent bulk drug used for intravenous injection.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410184771.0A CN105084393A (en) | 2014-05-05 | 2014-05-05 | Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410184771.0A CN105084393A (en) | 2014-05-05 | 2014-05-05 | Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105084393A true CN105084393A (en) | 2015-11-25 |
Family
ID=54565849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410184771.0A Pending CN105084393A (en) | 2014-05-05 | 2014-05-05 | Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105084393A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108394937A (en) * | 2018-03-26 | 2018-08-14 | 宁夏大学 | Vulcanize the preparation method of ferromanganese solid solution and its application as lithium ion battery negative material |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251962A (en) * | 2012-02-17 | 2013-08-21 | 苏州迈格锐意医药科技有限公司 | Magnetic resonance contrast material and preparation method thereof, and contrast agent |
| CN103449477A (en) * | 2012-05-29 | 2013-12-18 | 顾世海 | Novel nanometer material contrast agent and application thereof |
| CN105000577A (en) * | 2014-04-23 | 2015-10-28 | 吴学文 | Preparation method of manganese hexacyanoferrate crystal nanoparticle and nuclear magnetic resonance contrast agent thereof |
-
2014
- 2014-05-05 CN CN201410184771.0A patent/CN105084393A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103251962A (en) * | 2012-02-17 | 2013-08-21 | 苏州迈格锐意医药科技有限公司 | Magnetic resonance contrast material and preparation method thereof, and contrast agent |
| CN103449477A (en) * | 2012-05-29 | 2013-12-18 | 顾世海 | Novel nanometer material contrast agent and application thereof |
| CN105000577A (en) * | 2014-04-23 | 2015-10-28 | 吴学文 | Preparation method of manganese hexacyanoferrate crystal nanoparticle and nuclear magnetic resonance contrast agent thereof |
Non-Patent Citations (1)
| Title |
|---|
| MIN LIU ET AL.: "Heat-induced magnetic properties changes of Mn3[Fe(CN)6]2•xH2O", 《PHYSICA STATUS SOLIDI C》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108394937A (en) * | 2018-03-26 | 2018-08-14 | 宁夏大学 | Vulcanize the preparation method of ferromanganese solid solution and its application as lithium ion battery negative material |
| CN108394937B (en) * | 2018-03-26 | 2020-07-17 | 宁夏大学 | Preparation method of manganese iron sulfide solid solution and application of manganese iron sulfide solid solution as negative electrode material of lithium ion battery |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Zhang et al. | When rare earth meets carbon nanodots: mechanisms, applications and outlook | |
| KR101642903B1 (en) | Preparation of hydrophilic material coated iron oxide nanoparticles and magnetic resonance contrast agent using thereof | |
| Zhang et al. | Bioinspired synthesis of gadolinium-based hybrid nanoparticles as MRI blood pool contrast agents with high relaxivity | |
| US8092783B2 (en) | Gadolinium containing prussian blue nanoparticles as nontoxic MRI contrast agents having high relaxivity | |
| CN105084392A (en) | Manganese potassium ferricyanide crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same | |
| CN104512910A (en) | Preparation method of manganese hexacyanoferrate and nanoparticle thereof | |
| CN105000577A (en) | Preparation method of manganese hexacyanoferrate crystal nanoparticle and nuclear magnetic resonance contrast agent thereof | |
| EP1960002A1 (en) | Aqueous dispersions of superparamagnetic single domain particles production and use thereof for diagnosis and therapy | |
| JP2008508267A (en) | Radicals and their use as paramagnetic reagents in DNP processing | |
| Liu et al. | Sequential growth of CaF 2: Yb, Er@ CaF 2: Gd nanoparticles for efficient magnetic resonance angiography and tumor diagnosis | |
| Jiang et al. | Self‐Confirming Magnetosomes for Tumor‐Targeted T1/T2 Dual‐Mode MRI and MRI‐Guided Photothermal Therapy | |
| CN105016358A (en) | Manganese hexacyanoferrate nanocrystal and preparation method of nuclear magnetic resonance contrast medium of same | |
| US20230138790A1 (en) | Multimodal pet/mri contrast agent and a process for the synthesis thereof | |
| CN105084391A (en) | Hexacyanomanganate-metal complex crystallizing nanoparticle and nuclear magnetic resonance contrast agent thereof | |
| Li et al. | The renal clearable magnetic resonance imaging contrast agents: state of the art and recent advances | |
| Ruan et al. | Recent development on controlled synthesis of Mn‐based nanostructures for bioimaging and cancer therapy | |
| EP1554734B1 (en) | Stabilized superparamagnetic particles | |
| Chen et al. | Ultrasmall MnSe Nanoparticles as T 1-MRI Contrast Agents for In Vivo Tumor Imaging | |
| CN104844839A (en) | Preparation method of magnetic fluorescent composite nanoparticle | |
| CN105084393A (en) | Manganese hexacyanoferrate crystalline nanoparticles and preparation method for nuclear magnetic resonance contrast agent using same | |
| CN106276974A (en) | The synthesis of Manganese hexacyanoferrate potassium crystallization | |
| CN105079824A (en) | Hexacyano-metal complex nanoparticle of manganese and nuclear magnetic resonance contrast agent of nanoparticle | |
| CN103316361B (en) | Stable nanoscale superparamagnetic iron oxide solution as well as preparation method and application thereof | |
| CN103449477A (en) | Novel nanometer material contrast agent and application thereof | |
| CN105883854A (en) | Manganese cobalticyanide crystal and nuclear magnetic resonance (NMR) contrast agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20151125 |